Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.
2.

Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.

Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN.

J Thorac Oncol. 2013 Jan;8(1):45-51. doi: 10.1097/JTO.0b013e318274a83e.

3.

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.

Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, Lu N.

Ann Oncol. 2013 Oct;24(10):2589-93. doi: 10.1093/annonc/mdt295. Epub 2013 Jul 31.

PMID:
23904459
4.

Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.

V Laffert M, Warth A, Penzel R, Schirmacher P, Jonigk D, Kreipe H, Schildhaus HU, Merkelbach-Bruse S, Büttner R, Reu S, Kerler R, Jung A, Kirchner T, Wölfel C, Petersen I, Rodriguez R, Jochum W, Bartsch H, Fisseler-Eckhoff A, Berg E, Lenze D, Dietel M, Hummel M.

Lung Cancer. 2013 Aug;81(2):200-6. doi: 10.1016/j.lungcan.2013.04.015. Epub 2013 May 10.

PMID:
23669200
5.

ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.

Arch Pathol Lab Med. 2014 Nov;138(11):1449-58. doi: 10.5858/arpa.2013-0388-OA. Epub 2014 Jun 2.

PMID:
24885803
6.

Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches.

Demidova I, Grinevich V, Avdalian A, Imyanitov E, Gikalo M, Savelov N, Novikova I, Samuilenkova O, Tiurin V, Ulianova E, Tsimafeyeu I, Tjulandin S.

Lung Cancer. 2017 Jan;103:17-23. doi: 10.1016/j.lungcan.2016.11.001. Epub 2016 Nov 13.

PMID:
28024691
7.

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Lee JS, Jheon S, Chung JH.

J Thorac Oncol. 2011 Mar;6(3):466-72. doi: 10.1097/JTO.0b013e31820b82e8.

8.

Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).

Shen Q, Wang X, Yu B, Shi S, Liu B, Wang Y, Xia Q, Rao Q, Zhou X.

Lung Cancer. 2015 Dec;90(3):492-8. doi: 10.1016/j.lungcan.2015.10.002. Epub 2015 Oct 21.

PMID:
26477969
9.

Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.

Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, Jiang L, Wei P, Diao XL, Li X, Cao Q, Tian XX.

PLoS One. 2013 May 31;8(5):e64821. doi: 10.1371/journal.pone.0064821. Print 2013.

10.

Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.

Wang Q, Zhao L, Yang X, Wei S, Zeng Y, Mao C, Lin L, Fu P, Lyu L, Li Z, Xiao H.

Lung Cancer. 2016 May;95:39-43. doi: 10.1016/j.lungcan.2016.02.014. Epub 2016 Mar 3.

PMID:
27040850
11.

ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.

Williams AS, Greer W, Bethune D, Craddock KJ, Flowerdew G, Xu Z.

Virchows Arch. 2016 Nov;469(5):533-540. Epub 2016 Aug 25.

PMID:
27562706
12.

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.

Vollbrecht C, Lenze D, Hummel M, Lehmann A, Moebs M, Frost N, Jurmeister P, Schweizer L, Kellner U, Dietel M, von Laffert M.

BMC Cancer. 2018 Nov 22;18(1):1158. doi: 10.1186/s12885-018-5070-6.

13.

Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.

Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, Stroiakovaski D, Popov M, Laktionov K, Gutorov S, Smolin A, Olshanskaya Y, Obukhova T.

Arch Pathol Lab Med. 2014 Jun;138(6):794-802. doi: 10.5858/arpa.2012-0762-OA.

PMID:
24878018
14.

Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.

Savic S, Diebold J, Zimmermann AK, Jochum W, Baschiera B, Grieshaber S, Tornillo L, Bisig B, Kerr K, Bubendorf L.

Lung Cancer. 2015 Aug;89(2):104-9. doi: 10.1016/j.lungcan.2015.05.012. Epub 2015 May 21.

PMID:
26056079
15.

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS.

Lung Cancer. 2012 Aug;77(2):288-92. doi: 10.1016/j.lungcan.2012.03.004. Epub 2012 Mar 31.

PMID:
22465695
16.

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA.

Histopathology. 2017 Feb;70(3):402-411. doi: 10.1111/his.13076. Epub 2016 Nov 15.

17.

A comparative analysis of immunohistochemistry and fluorescent in situ hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: A search for a testing algorithm.

Wagle PB, Jambhekar NA, Kumar R, Prabhash K, Pramesh CS, Desai SB, Noronha V, Karimundackal G, Shah A, Joshi A, Laskar SG, Jiwnani S, Pai T, Agarwal JP.

Indian J Cancer. 2017 Jan-Mar;54(1):148-154. doi: 10.4103/ijc.IJC_202_17.

18.

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.

Marchetti A, Di Lorito A, Pace MV, Iezzi M, Felicioni L, D'Antuono T, Filice G, Guetti L, Mucilli F, Buttitta F.

J Thorac Oncol. 2016 Apr;11(4):487-95. doi: 10.1016/j.jtho.2015.12.111. Epub 2016 Feb 22.

19.

[Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].

Fang F, Wang YX, Hu ST, Yang L, Di J, Liu DG, Lyu N.

Zhonghua Bing Li Xue Za Zhi. 2018 Jun 8;47(6):432-437. doi: 10.3760/cma.j.issn.0529-5807.2018.06.009. Chinese.

PMID:
29886587
20.

Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.

Rosenblum F, Hutchinson LM, Garver J, Woda B, Cosar E, Kurian EM.

Cancer Cytopathol. 2014 Nov;122(11):810-21. doi: 10.1002/cncy.21467. Epub 2014 Aug 5.

Supplemental Content

Support Center